Clinical TrialJun 25, 2026, 07:01 AM
Satellos to Present SAT-3247 Clinical Updates at ICNMD 2026
AI Summary
Satellos Bioscience Inc. announced it will present new data from its SAT-3247 clinical development program at the 19th International Congress on Neuromuscular Diseases (ICNMD) in Florence, Italy, from July 7–11, 2026. The presentations will include a poster detailing six-month follow-up data from participants who completed the Phase 1b SAT-3247-CL-101 trial and enrolled in the ongoing Phase 2 TRAILHEAD (LT-001) trial. Wildon Farwell, MD, MPH, Satellos' Chief Medical Officer, will present both the poster and a Showcase Theatre presentation on advancing muscle repair with SAT-3247, an investigational oral small molecule for degenerative muscle diseases like Duchenne muscular dystrophy.
Key Highlights
- Satellos to present new data from its SAT-3247 clinical development program.
- Updates will be featured at the 19th International Congress on Neuromuscular Diseases (ICNMD) in Florence, Italy.
- The conference is scheduled from July 7–11, 2026.
- A poster will highlight six-month follow-up data from Phase 1b participants in the Phase 2 TRAILHEAD (LT-001) trial.
- Chief Medical Officer Wildon Farwell, MD, MPH, will deliver the poster and a Showcase Theatre presentation.
- SAT-3247 is an investigational oral small molecule for degenerative muscle diseases, including Duchenne muscular dystrophy (DMD).
- The drug candidate is currently in Phase 2 clinical studies (TRAILHEAD and BASECAMP).
Price Impact
More from MSLE